NeurAxis, Inc.AMEX: NRXS

NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference

· Issued by NeurAxis, Inc. via GlobeNewswire

Summary by 6ix AI

NeurAxis, Inc., a medical technology company commercializing neuromodulation (nerve stimulation) therapies for chronic conditions in children and adults, will give a webcast presentation and hold virtual one-on-one investor meetings at the Lytham Partners Fall 2026 Investor Conference, held virtually on September 29-30, 2026.

Key details

  • The webcast presentation is scheduled for 11:45 a.m. ET on Tuesday, September 29, 2026, and will be available for replay after the event.
  • Management will take part in virtual one-on-one meetings throughout the event, arranged through Lytham Partners.

6ix AI wrote this summary from the release below and checked it against the release.

CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Company Webcast

The webcast presentation will take place at 11:45 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/lJ5aBmzWwkZ. The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [email protected] or register for the event at https://lythampartners.com/fall2026invreg/.

About NeurAxis, Inc.

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia, including FD-linked nausea symptoms in patients ages 8 and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

Contacts:

Company
NeurAxis, Inc.
[email protected]

Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
[email protected]

NeurAxis, Inc. on 6ix

Story so far

Earlier from NeurAxis

Later from NeurAxis

All NeurAxis news releases